Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma

Domenico Bellomo, Suzette M. Arias-Mejias, Chandru Ramana, Joel B. Heim, Enrica Quattrocchi, Sindhuja Sominidi-Damodaran, Alina G. Bridges, Julia S. Lehman, Tina J. Hieken, James W. Jakub, Mark R. Pittelkow, David J. DiCaudo, Barbara A. Pockaj, Jason C. Sluzevich, Mark A. Cappel, Sanjay P. Bagaria, Charles Perniciaro, Félicia J. Tjien-Fooh, Martin H. van Vliet, Jvalini DwarkasingAlexander Meves

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

PURPOSE More than 80% of patients who undergo sentinel lymph node (SLN) biopsy have no nodal metastasis. Here, we describe a model that combines clinicopathologic and molecular variables to identify patients with thin- and intermediate-thickness melanomas who may forgo the SLN biopsy procedure because of their low risk of nodal metastasis. PATIENTS AND METHODS Genes with functional roles in melanoma metastasis were discovered by analysis of next-generation sequencing data and case-control studies. We then used polymerase chain reaction to quantify gene expression in diagnostic biopsy tissue across a prospectively designed archival cohort of 754 consecutive thin- and intermediate-thickness primary cutaneous melanomas. Outcome of interest was SLN biopsy metastasis within 90 days of melanoma diagnosis. A penalized maximum likelihood estimation algorithm was used to train logistic regression models in a repeated cross-validation scheme to predict the presence of SLN metastasis from molecular, clinical, and histologic variables. RESULTS Expression of genes with roles in epithelial-to-mesenchymal transition (glia-derived nexin, growth differentiation factor 15, integrin-β3, interleukin 8, lysyl oxidase homolog 4, transforming growth factor-β receptor type 1, and tissue-type plasminogen activator) and melanosome function (melanoma antigen recognized by T cells 1) were associated with SLN metastasis. The predictive ability of a model that only considered clinicopathologic or gene expression variables was outperformed by a model that included molecular variables in combination with the clinicopathologic predictors Breslow thickness and patient age (area under the receiver operating characteristic curve, 0.82; 95% CI, 0.78 to 0.86; SLN biopsy reduction rate, 42%; negative predictive value, 96%). CONCLUSION A combined model that included clinicopathologic and gene expression variables improved the identification of patients with melanoma who may forgo the SLN biopsy procedure because of their low risk of nodal metastasis.

Original languageEnglish (US)
Pages (from-to)319-334
Number of pages16
JournalJCO Precision Oncology
Volume3
DOIs
StatePublished - 2019

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma'. Together they form a unique fingerprint.

  • Cite this

    Bellomo, D., Arias-Mejias, S. M., Ramana, C., Heim, J. B., Quattrocchi, E., Sominidi-Damodaran, S., Bridges, A. G., Lehman, J. S., Hieken, T. J., Jakub, J. W., Pittelkow, M. R., DiCaudo, D. J., Pockaj, B. A., Sluzevich, J. C., Cappel, M. A., Bagaria, S. P., Perniciaro, C., Tjien-Fooh, F. J., van Vliet, M. H., ... Meves, A. (2019). Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma. JCO Precision Oncology, 3, 319-334. https://doi.org/10.1200/PO.19.00206